Acetazolamide, sold under the trade name Diamox, is a carbonic anhydrase inhibitor that is used to treat glaucoma, epileptic seizures, benign intracranial hypertension (pseudotumor cerebri), altitude sickness, cystinuria, and dural ectasia. Acetazolamide is available as a generic drug and is also used as a diuretic.
Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients with acute decompensated heart failure, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.
Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.
Researchers report a case of a young male patient who came in with a headache to an emergency room. He had increased intracranial pressure and tested positive for SARS-CoV-2, suggesting new headaches during the pandemic should not be ignored.
Early reports of COVID-19 symptoms and the compelling need to quickly identify treatment options and curb the growing number of critically ill patients have led to erroneous and potentially dangerous comparisons between COVID-19 and other respiratory diseases like high altitude pulmonary edema, or HAPE.
A new study finds that a medication commonly prescribed to prevent and combat symptoms of acute mountain sickness does not reduce exercise performance at high altitudes. This may be especially important for military personnel and first responders not accustomed to working above sea level.
A drug used to treat altitude sickness -- as well as glaucoma, epilepsy, heart failure and seizures -- may also offer significant gains for patients with a fast-growing brain tumor known as glioblastoma, according to a study published July 4, 2018, in the journal Science Translational Medicine.
Research led by the University of Birmingham, published today in Science Translational Medicine, has discovered that a drug commonly used to treat patients with either obesity or Type II diabetes could be used as a novel new way to lower brain pressure.
Trekking and mountain climbing are quickly growing in popularity, but.one of the challenges that climbers face is acute mountain sickness (AMS). Previous studies have shown that ibuprofen is an effective way to reduce the risk of AMS.
A team of biomedical engineering researchers at the University of Arkansas have identified a cause of fluid swelling of the brain, or cellular edema, that occurs during a concussion.
International tourism exceeds 1.2 billion persons each year, with more than 20 percent of travelers reporting some type of illness.
University of the Basque Country researchers have studied the nutritional and health situations existing at high altitudes as well as the routinely used nutritional ergogenic and pharmacological aids. According to their study, the possible interactions between drugs and food and nutrients taken may endanger the mountaineer’s health if all this is not conducted under strict control.
In an NIH-funded clinical trial, led at Saint Louis University by professor of ophthalmology Sophia Chung, M.D., researchers aim to bring sight back to those who have lost vision due to idiopathic intracranial hypertension.
An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health.
A team of interventional neuroradiologists and neurosurgeons at Johns Hopkins reports wide success with a new procedure to treat pseudotumor cerebri, a rare but potentially blinding condition marked by excessive pressure inside the skull, caused by a dangerous narrowing of a vein located at the base of the brain.
Patients with obstructive sleep apnea can better control their symptoms when traveling to higher altitudes by combining autoadjusted continuous positive airway pressure with acetazolamide, research suggests.
For individuals with obstructive sleep apnea traveling to higher altitudes (which may exacerbate symptoms), use of a combination therapy resulted in improvement in symptoms including reduced insomnia and better control of sleep apnea, according to a preliminary study published in the December 12 issue of JAMA.
Altitude sickness manifests by symptoms including a headache, fatigue, dizziness and sometimes nausea and vomiting. In addition, patients most likely also feel like they are working harder to breathe, like they are constantly trying to catch their breath. It normally takes days to weeks to fully acclimate to a higher altitude. It affects between 25 percent and 40 percent of the population and can be debilitating.
Measuring specific, exercise-related responses can help physicians determine who may be more at risk for severe high altitude illness (SHAI), according to a study conducted by researchers in France. The researchers also found that taking acetazolamide (ACZ), a drug frequently prescribed to prevent altitude illness, can reduce some of the risk factors associated with SHAI.
A rare but increasingly more common disease striking overweight, younger women is the focus of a clinical trial at Michigan State University, where an osteopathic physician is testing the effectiveness of a certain drug against a potentially blindness-causing ailment.
As the American military rushes to confront adversaries in some of the world's highest mountain ranges, the Department of Defense is giving $4 million to the Altitude Research Center at the University of Colorado School of Medicine to develop revolutionary ways to combat high altitude sickness in soldiers, sailors and marines.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.